Avantor (NYSE:AVTR – Get Free Report) and IceCure Medical (NASDAQ:ICCM – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, earnings, valuation, profitability and dividends.
Profitability
This table compares Avantor and IceCure Medical’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Avantor | -1.25% | 10.91% | 5.34% |
| IceCure Medical | -513.95% | -243.68% | -123.94% |
Earnings & Valuation
This table compares Avantor and IceCure Medical”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Avantor | $6.78 billion | 1.23 | $711.50 million | ($0.13) | -94.38 |
| IceCure Medical | $3.29 million | 13.80 | -$15.32 million | ($0.26) | -2.54 |
Avantor has higher revenue and earnings than IceCure Medical. Avantor is trading at a lower price-to-earnings ratio than IceCure Medical, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Avantor and IceCure Medical, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Avantor | 1 | 11 | 3 | 0 | 2.13 |
| IceCure Medical | 1 | 1 | 2 | 0 | 2.25 |
Avantor currently has a consensus target price of $13.60, indicating a potential upside of 10.84%. IceCure Medical has a consensus target price of $2.64, indicating a potential upside of 298.58%. Given IceCure Medical’s stronger consensus rating and higher possible upside, analysts clearly believe IceCure Medical is more favorable than Avantor.
Risk and Volatility
Avantor has a beta of 0.93, meaning that its share price is 7% less volatile than the S&P 500. Comparatively, IceCure Medical has a beta of 0.29, meaning that its share price is 71% less volatile than the S&P 500.
Institutional & Insider Ownership
95.1% of Avantor shares are owned by institutional investors. Comparatively, 0.6% of IceCure Medical shares are owned by institutional investors. 1.2% of Avantor shares are owned by insiders. Comparatively, 2.4% of IceCure Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Summary
Avantor beats IceCure Medical on 9 of the 14 factors compared between the two stocks.
About Avantor
Avantor, Inc. engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips. It also provides equipment and instrumentation products, including filtration systems, virus inactivation systems, incubators, analytical instruments, evaporators, ultra-low-temperature freezers, biological safety cabinets, and critical environment supplies. In addition, the company offers services and specialty procurements comprising onsite lab and production, clinical, equipment, procurement and sourcing, and biopharmaceutical material scale-up and development services. Further, it provides scientific research support services, such as DNA extraction, bioreactor servicing, clinical and biorepository, and compound management services. The company was founded in 1904 and is headquartered in Radnor, Pennsylvania.
About IceCure Medical
IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.
